the science behind doxorubicin
Doxorubcin is an antibiotic used to treat cancers, it works by intercalating DNA. This means it makes DNA ineffective, this is effective because by doing so you stop the quick cell replication, which inhibits cancer cell growth, but also at the expense of normal cell growth. This leads to a host of complications, the most serious of which is cardiomyopathy. Due to this side effect all patients that are being started on doxorubicin must first have an echocardiogram and have a maximum dose of doxorubicin to prevent cardiomyopathy. AEZS-108 has the promise of decreasing the side effect of the doxorubicin while at the same time inhibiting the progression of a variety of cancer cell types, with endometrial cancer being the type being brought before the FDA now. This is an international study with numerous enrollees. This is great news for the company, as the phase 2 studies were so effective that it was very easy to recruit for phase 3.
This company has 2 medications that are close to FDA approval. Macrilen is being brought for approval as a medication to use to diagnose AGHD as an oral test. This would become the method of choice to diagnose AGHD the world over. Makes sense to diagnose with an oral formulation over an expensive IV test, insurances and patients will dictate the change. This seems to be an almost guarantee of approval, no red flags that are in the picture. This approval of itself should drive up the market cap of this company.
However we are not solely focusing on Macrilen, we are also looking at Zoptarelin. This will be the game changer. If the phase 3 trials are positive, AEZS will skyrocket. Because it doesn't have just implications for endometrial cancer (which affects 1 in 8 women) but also LHRH has indications that it is effective in prostate, colon, melanoma, lymphoma, and sarcomas.
This would be an amazing feat for a pharmaceutical company of its size.
As if that weren't enough for such a small company it also has a medication for cancer induced cachexia as well as a possible anti cancer vaccine. This is amazing news for investors in this stock.
(From yahoo foro)
